<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093741</url>
  </required_header>
  <id_info>
    <org_study_id>061101</org_study_id>
    <nct_id>NCT02093741</nct_id>
  </id_info>
  <brief_title>ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)</brief_title>
  <official_title>ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on the&#xD;
      safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection (SWFI)&#xD;
      during routine clinical practice in children until 12 years of age. This surveillance study&#xD;
      is a post-licensure commitment for ADVATE reconstituted in 2 mL SWFI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2013</start_date>
  <completion_date type="Actual">January 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 20, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all local and general, hypersensitivity and infusion-related reactions, irrespective of product-related causality for the adverse events (AEs).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and type of adverse events (or adverse experiences) (AEs) considered by the investigator to be causally related to ADVATE reconstituted in 2 mL sterile water for injection (SWFI)</measure>
    <time_frame>6 months</time_frame>
    <description>Causally related = possibly or probably related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Factor VIII (FVIII) inhibitors in all participants</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Factor VIII (FVIII) inhibitors in Previously Treated Patients (PTPs) (&gt; 50 Exposure Days (EDs)) with baseline Factor VIII (FVIII) &lt; 1% and no history of FVIII inhibitors prior to study entry</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Factor VIII (FVIII) inhibitors in Previously Treated Patients (PTPs) (&gt; 50 Exposure Days (EDs)) with baseline Factor VIII (FVIII) ≤ 2% and no history of FVIII inhibitors prior to study entry</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective hemostatic effectiveness rating of excellent, good, fair, or none for each bleeding episode treated</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes treated with 1, 2, 3, ≥ 4 infusions of ADVATE reconstituted in 2 mL sterile water for injection (SWFI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of ADVATE reconstituted in 2 mL sterile water for injection (SWFI) administered to treat each bleeding episode</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall effectiveness of prophylaxis in participants who are on a prophylactic regimen</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment rating of hemostatic effectiveness of ADVATE reconstituted in 2 mL sterile water for injection (SWFI) in surgical or dental procedures</measure>
    <time_frame>6 months</time_frame>
    <description>Global assessment rating = excellent, good, fair, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Factor VIII (FVIII) treatment satisfaction and preference ratings from caregiver between ADVATE reconstituted in 5 mL and 2 mL sterile water for injection (SWFI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Factor VIII (FVIII) infusion volume and time to mix and infuse FVIII treatment between ADVATE reconstituted in 5 mL and 2 mL sterile water for injection (SWFI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Congenital Factor VIII (FVIII) Deficiency</condition>
  <arm_group>
    <arm_group_label>ADVATE - 2mL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]</intervention_name>
    <description>The investigators shall determine all treatment regimens according to product labeling information and standard practice.</description>
    <arm_group_label>ADVATE - 2mL</arm_group_label>
    <other_name>Antihemophilic Factor (Recombinant)- Plasma/albumin free method (rAHF-PFM)</other_name>
    <other_name>ADVATE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include 60 evaluable participants aged = 12 years with severe or&#xD;
        moderately severe hemophilia A (Factor VIII (FVIII) = 2%) with documented prior exposure to&#xD;
        FVIII concentrates.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe or moderately severe hemophilia A (baseline Factor VIII (FVIII) ≤ 2%)&#xD;
&#xD;
          -  ≤12 years of age&#xD;
&#xD;
          -  Participant's legally authorized representative(s) has provided written informed&#xD;
             consent&#xD;
&#xD;
          -  Participant is prescribed ADVATE and will only receive ADVATE reconstituted in 2 mL&#xD;
             sterile water for injection (SWFI)&#xD;
&#xD;
          -  Documented history of prior exposure to ADVATE&#xD;
&#xD;
          -  Documented evidence of negative inhibitor test result during ≤10 EDs prior to study&#xD;
             entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  Known allergic reaction to mouse or hamster proteins&#xD;
&#xD;
          -  Participant has a requirement for a major surgical procedure at the time of enrollment&#xD;
&#xD;
          -  Participant has no prior exposure to a FVIII concentrate&#xD;
&#xD;
          -  Participant currently being treated with an immune tolerance induction (ITI) regimen&#xD;
&#xD;
          -  Participant has been diagnosed with an inherited or acquired hemostatic defect other&#xD;
             than hemophilia A (eg, qualitative platelet defect or von Willebrand disease)&#xD;
&#xD;
          -  Participant has participated in another clinical study involving an investigational&#xD;
             product (IP) or investigational device within 30 days prior to enrollment or is&#xD;
             scheduled to participate in another clinical study involving an IP or investigational&#xD;
             device or PASS registry during the course of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Pellegrin, Hématologie - CRTH</name>
      <address>
        <city>BORDEAUX Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Générale, CTH</name>
      <address>
        <city>Chambery Cedex</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRTH Laboratoire d'Hématologie CHRU - Hôpital du Bocage</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Memorial Hospital, Service de Pédiatrie</name>
      <address>
        <city>REIMS Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes Cedex 09</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord, Pédiatrie</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Purpan, CRTH - Pavillon Sénac</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital de Brabois- CRTH - Laboratoire Hémato-Hémostase</name>
      <address>
        <city>VANDOEUVRE-LES-NANCY Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken des Saarlandes, Klinik für pädiatrische Onkologie und Hämatologie</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Olgahospital, Pädiatrie 5</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pál Children's Hospital, Department of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1131</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén County Hospital, Pediatric Dep</name>
      <address>
        <city>Miskolc</city>
        <zip>3629</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mohacsi Korhaz, Department of Pediatrics</name>
      <address>
        <city>Mohacs</city>
        <zip>7700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Egyetemi Oktatokorhaz, Department of Pediatrics</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fc24db2bf003ab457db</url>
    <description>To obtain more information on the study, click here/on this link.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

